Clinical Implications of the Multicenter Automatic Defibrillator Implantation Trial (MADIT): An Investigator's Perspective Arthur J. Moss OriginalPaper Pages: 6 - 7
Clinical Implications of the Antiarrhythmics Versus Implantable Defibrillators (AVID) Trial: The Investigators' Perspective H. Leon Green OriginalPaper Pages: 8 - 10
Canadian Implantable Defibrillator Study (CIDS): Perspective of the Principal Investigators S.J. ConnollyM. GentR.S. Roberts OriginalPaper Pages: 11 - 12
Clinical Implications of the CABG Patch Trial: An Investigator's Perspective John P. DiMarco OriginalPaper Pages: 13 - 15
The Cardiac Arrest Study Hamburg (CASH) Riccardo CappatoJürgen SiebelsCash Investigators OriginalPaper Pages: 16 - 16
Clinical Implications of MADIT, AVID, CIDS, CABG Patch Trial and CASH: A North American Perspective Jeremy N. Ruskin OriginalPaper Pages: 17 - 20
Clinical Implications of MADIT, AVID, CIDS, the CABG Patch Trial and CASH: A European Perspective M.M. GallagherA.J. Camm OriginalPaper Pages: 21 - 22
Clinical Implications of the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial (CAMIAT) John A. Cairns OriginalPaper Pages: 23 - 25
Clinical Implications of the European Myocardial Infarct Amiodarone Trial (EMIAT) A. John Camm OriginalPaper Pages: 26 - 27
Clinical Implications of the Survival with Oral D-Sotalol (SWORD) Trial: An Investigation of Patients with Left Ventricular Dysfunction after Myocardial Infarction Craig M. Pratt OriginalPaper Pages: 28 - 29
Clinical Implications of the CAMIAT, EMIAT and SWORD Trials: A North American Perspective Jeffrey L. Anderson OriginalPaper Pages: 30 - 33
Clinical Implications of the CAMIAT, EMIAT and SWORD Trials: A European Perspective Martin BorggrefeWilhelm HaverkampGünter Breithardt OriginalPaper Pages: 34 - 35
Clinical Implications of the CAMIAT, EMIAT and SWORD Trials: A South American Perspective Hernán C. Doval OriginalPaper Pages: 36 - 37
The ATRAMI Prospective Study: Implications for Risk Stratification after Myocardial Infarction Peter J. Schwartz OriginalPaper Pages: 38 - 40
Clinical Implications of ATRAMI: A Clinician's Perspective Raul D. MitraniRobert J. Myerburg OriginalPaper Pages: 41 - 43
Spaf III Trial: Of Risk Stratification and Minimal Effective Warfarin Intensity Joseph L. Blackshear OriginalPaper Pages: 44 - 48
Clinical Implications of the Stroke Prevention in Atrial Fibrillation III Trial: A Clinician's Perspective Gregory Y.H. Lip OriginalPaper Pages: 49 - 51
Evolving Indications for Permanent Pacing in Patients with Vasovagal Syncope Robert S. SheldonMichael GentStuart J. Connolly OriginalPaper Pages: 52 - 53
Clinical Implications of the North American Vasovagal Pacemaker Study David G. BendittWilliam Fabian OriginalPaper Pages: 54 - 56
Conversion of Atrial Fibrillation: Pills, Shots, or Shocks? Philip J. Podrid OriginalPaper Pages: 64 - 68
EP Practice Patterns, Reimbursement and Health Care Policy in South Korea You-Ho KimSung-Soon Kim OriginalPaper Pages: 71 - 72
EP Practice Patterns, Reimbursement and Health Care Policy in Israel Michael GliksonZeev Rotstein OriginalPaper Pages: 77 - 79
EP Practice Patterns, Reimbursement and Health Care Policy in France Pierre Maison-BlancheBruno Cauchemez OriginalPaper Pages: 80 - 80
EP Practice Patterns, Reimbursement and Health Care Policy in Canada D. George WyseL. Brent Mitchell OriginalPaper Pages: 83 - 85
Electrophysiology Practice in a Health Maintenance Organization Simón Milstein OriginalPaper Pages: 89 - 90
Working Toward an Efficient Electrophysiology Practice Antonio PacificoPhilip D. Henry OriginalPaper Pages: 91 - 93
What to Expect from the 105th Congress: A View from Inside the Beltway Dan Nickelson OriginalPaper Pages: 97 - 98
Workforce Planning in a Changing Environment: How Much is Enough? Alan Morgan OriginalPaper Pages: 99 - 100
